| Public | NASDAQ:CLVS |
| Date | 11/11 |
| Raised | $130M |
| Post IPO Valuation |
| Website | clovisoncology.com |
| @clovisoncology | |
| Category | BioTech |
| Employees | |
| Founded | 2009 |
| Description | Oncology Compound Licencing Company |
| Avila Therapeutics | 1/12 |
| TOTAL | $145M |
| FUNDING TOTAL | $145M |
| Series A, 5/09 Domain Associates New Enterprise Associates Versant Ventures Aberdare Ventures Abingworth Frazier Healthcare Ventures ProQuest Investments | $145M |
Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets.
